Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer

2.1 Niraparib (Zejula, GSK) has a marketing authorisation for 'the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy'.

2.2 The dosage schedule is available in the summary of product characteristics for niraparib.

2.3 The list price for niraparib is £4,500 for a 56‑tablet pack of 100 mg tablets; £6,750 for an 84‑tablet pack of 100 mg tablets (excluding VAT; BNF online, accessed August 2021).

2.4 The company has a commercial arrangement. This makes niraparib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.